Hims & Hers Stock Plunges as Profit Vanishes and Growth Engine Sputters
Hims & Hers Health (HIMS) reported a Q3 net loss of $33M, missing analyst profit expectations. Revenue rose 49% YoY to $890.4M, but subscriber growth slowed. The company lowered its full-year EBITDA forecast. Shares fell 12% on the news.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to keep the stock under pressure in the near term.
Market read
Earnings surprise and guidance downgrade make this a notable event for traders with exposure to HIMS.
What to watch
International sales surged 4x, indicating growth potential beyond current profitability concerns.
Background
Hims & Hers Health reported its Q3 results, missing profit expectations and lowering full‑year guidance.
Ticker impact
Q3 loss of $33M, EPS -0.14 vs expected +0.06, revenue up 49% but guidance below estimates, shares down ~12% after earnings.
likely further downside as market prices in weaker outlook
Profit surprise and guidance cut are fresh, material facts that typically trigger bearish moves.
Market effects
Telehealth and digital health sector may face broader scrutiny as earnings miss highlights cost pressures.
U.S. market sentiment may dip slightly in health‑tech stocks.
Limited to investors tracking U.S. digital health equities.
Counterpoint
If the weight‑loss drug pipeline gains traction, the stock could rebound despite short‑term miss.
Key entities
- companyHims & Hers Health
U.S. telehealth and consumer health company (NYSE:HIMS).
